Skip to NavigationSkip to content

AbbVie's Rinvoq impresses at Phase 3 in active psoriatic arthritis sub-population

Published on 31/10/19 at 02:28pm

AbbVie has unveiled new Phase 3 data on two doses of its JAK inhibitor Rinvoq (upadacitinib), showing that the therapy met its primary endpoint in the treatment of  active psoriatic arthritis in adult patients who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs (bDMARDs).

The data revealed that both 15mg and 30mg formulations generated an ACR20 response on the American College of Rheumatology’s measure of the disease in 57% and 64% of patients respectively, following 12 weeks of treatment compared to 24% with placebo. Furthmore, 32% and 38% of patients receiving these dosages achieved ACR50 compared to 5% with placebo, and 9% and 17% scored ACR70 versus 0.5% of placebo patients.

The study also noted that Rinvoq patients also reported greater improvements in physical function after 12 weeks according to the Health Assessment Questionnaire Disability Index, and 52% and 57% of patients reported 75% improvement in skin symptoms on the Psoriasis Area Severity Index after 16 weeks compared to 16% with placebo.

The study also met all of its ranked secondary endpoints compared to placebo.

“Too many people living with psoriatic arthritis still fail to achieve their treatment goals, underscoring a clear medical need for additional therapeutic options,” said Dr Michael Severino, Vice Chairman and President at AbbVie. “We are pleased with these data, which show the potential of Rinvoq to improve outcomes for people with psoriatic arthritis across a variety of symptoms. Data from this Phase 3 study will support regulatory submissions for Rinvoq in psoriatic arthritis.”

The company confirmed it would present the full results of the study at an upcoming medical conference.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches